术前新辅助化疗对ⅠB2～ ⅡB 期宫颈癌的 近期疗效观察
Short2term Therapeutic Value of Neoadjuvant Chemotherapy before Operation in Patients with Stage ⅠB2～ ⅡB Cervical Carcinoma
-
摘要: 目的 探讨ⅠB2～ ⅡB 期宫颈癌术前应用新辅助化疗的近期疗效。方法 收集我院2001～2006 年间ⅠB2～ ⅡB 期宫颈癌而行手术治疗患者78 例,其中40 例在手术前行新辅助化疗1～2 疗程 (A 组), 38 例在手术前未行新辅助化疗(B 组) 。比较2 组的化疗疗效及手术疗效。结果 新辅助化疗的总有效率为85 %, 可有效改善患者临床分期:A 组与B 组之间的术后盆腔淋巴结阳性率及宫旁脉管癌栓发生率之间的差异有统计学意义( P < 0. 05) 。结论 新辅助化疗可有效改善宫颈癌临床分期,显著提高宫颈癌手术疗效。Abstract: Objective To investigate the therapeutic value of neoadjuvant chemotherapy before operation in patient s with stage ⅠB2～ ⅡB cervical carcinoma. Methods Totally 78 cases of cervical carcinoma in stage ⅠB2 ～ ⅡB were operated in our hospital f rom 2001 to 2006, they were randomly divided into Group A(40 cases) who received neoadjuvant chemotherapy for 1～2 cycles before surgery and Group B (38 cases) who were directly operated. We compared the chemotherapy effect and surgery effect . Results The overall response rate was 85 %, which can improved the cancer's clinic stage. The rates of posi2 tive pelvic lymph node metastasis and paramet rial invasion in Group A were significantly less than those in Group B( P < 0. 05) . Conclusion NACT can improve the stage of cervix carcinoma and the surgery effect .
下载:
